Danielle A. Baribeau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Danielle A. Baribeau has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
Evdokia Anagnostou
University of Toronto, Faculty of Medicine Toronto Ontario Canada
5 shared publicationsPeter Szatmari
Univ Toronto, Dept Psychiat, Toronto, ON, Canada
4 shared publicationsEleanor Pullenayegum
Hosp Sick Children Res Inst, Child Hlth Evaluat Sci, Toronto, ON, Canada
3 shared publications- Gregory Costain
The Hospital for Sick Children
3 shared publications - Jacob A. S. Vorstman
The Hospital for Sick Children
3 shared publications Jesiqua Rapley
Holland Bloorview Kids Rehabilitation Hospital, 150 Kilgour Road, Toronto, ON, M4G 1R8, Canada
3 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by Springer Nature in Journal of Rare Diseases
- Vol. 5 (1) , 111
A primer on expert elicitation with IDEA (Investigate Discuss Estimate Aggregate) for rare disease trialists
In clinical trials for rare diseases, small patient populations constrain recruitment, limiting data collection. Expert elicitation, the process of extracting expert beliefs into quantitative expressions, can act as a source of evidence in a setting with limited data. Expert judgement can be combined with trial data through the prior distribution in a Bayesian trial. This approach makes the most use out of the available information and possible trial recruitment, unlike conventional approaches that rely on trial data alone. Previous elicitations for rare disease trial prior distributions have used ad hoc approaches, rather than an established protocol designed to limit biases in judgement. This practical guide introduces rare disease clinical investigators to expert elicitation using the IDEA (Investigate, Discuss, Estimate, Aggregate) protocol. IDEA is a structured elicitation technique where experts individually estimate quantities, discuss their answers, then revise their estimates before aggregation into a final distribution. In an elicitation for a trial, experts can either estimate the control arm response or the treatment effect. The elicitation estimates then inform the design and analysis of the trial. IDEA has previously been described in a general context, but this paper provides tailored recommendations for conducting an elicitation for a clinical trial for a rare disease. By outlining practical steps to using IDEA, we aim to promote more structured, transparent practices that will increase the uptake and acceptance of expert elicitation to improve clinical trials for rare diseases.
- 4 November 2026
- Published by Springer Nature in Journal of Rare Diseases
- Vol. 5 (1) , 111
Open AccessA primer on expert elicitation with IDEA (Investigate Discuss Estimate Aggregate) for rare disease trialists
In clinical trials for rare diseases, small patient populations constrain recruitment, limiting data collection. Expert elicitation, the process of extracting expert beliefs into quantitative expressions, can act as a source of evidence in a setting with limited data. Expert judgement can be combined with trial data through the prior distribution in a Bayesian trial. This approach makes the most use out of the available information and possible trial recruitment, unlike conventional approaches that rely on trial data alone. Previous elicitations for rare disease trial prior distributions have used ad hoc approaches, rather than an established protocol designed to limit biases in judgement. This practical guide introduces rare disease clinical investigators to expert elicitation using the IDEA (Investigate, Discuss, Estimate, Aggregate) protocol. IDEA is a structured elicitation technique where experts individually estimate quantities, discuss their answers, then revise their estimates before aggregation into a final distribution. In an elicitation for a trial, experts can either estimate the control arm response or the treatment effect. The elicitation estimates then inform the design and analysis of the trial. IDEA has previously been described in a general context, but this paper provides tailored recommendations for conducting an elicitation for a clinical trial for a rare disease. By outlining practical steps to using IDEA, we aim to promote more structured, transparent practices that will increase the uptake and acceptance of expert elicitation to improve clinical trials for rare diseases.
- Open Access
- 28 October 2026
- Published by MDPI AG in Preprints.org
Designing Quasi-Experimental Single Participant Studies for Targeted Genetic Therapies with a One-Off Impact
Background: Genetic therapies aim to create targeted interventions that treat, prevent or manage genetic disorders, holding substantial promise for many pediatric diseases with underlying genetic causes. As emerging genetic therapies are increasingly being tailored to individual patients, evaluating their efficacy is challenging. Standard N-of-1 trial designs that require repeated crossovers between experimental and control conditions are infeasible as many genetic therapies produce one-time, irreversible effects. Quasi-experimental single-participant designs with pre- and post- intervention periods are a promising alternative in this context where interrupted time series (ITS) analysis can be applied. Herein, we evaluated and compared different design and statistical elements for single participant studies of novel genetic therapies. Methods: We simulated designs using pre- and post-intervention treatment periods examined with ITS models under different assumptions about treatment effects. Changes in a continuous study outcome were assumed to be linear with varying standard deviations (SD). Different frequentist and Bayesian statistical models were compared. Trial performance was evaluated across varying pre-treatment lengths, effect sizes, outcome measurement frequencies, and outcome SD. Patient and family engagement examined the feasibility of study design elements. Results: Using frequentist methods, three selected statistical models achieved similar optimal performance for a study duration of 2 years, yielding power of approximately 80% or higher while maintaining type I error rates around 5%. Simulations suggested studies with balanced pre-post intervention period lengths, larger treatment effects, lower outcome SD, and more frequent outcome assessments had the highest statistical power. Type I error rates were insensitive to outcome SD changes. Less frequent outcome measurement improved trial feasibility from a family perspective. Similar performance was observed when applying Bayesian analyses with minimally informative priors under the same trial design assumptions. Incorporating patient and caregiver perspectives identified additional strategies to improve feasibility and acceptability of the trial designs beyond statistical considerations. Conclusions: Quasi-experimental single participant studies with ITS analysis provide a feasible framework for evaluating novel genetic treatment effect in rare diseases. Appropriate statistical approaches and design parameters are critical for achieving adequate power while maintaining type I error control. Meaningful patient and family engagement during study design is critical for feasibility.
- 28 October 2026
- Published by MDPI AG in Preprints.org
Open AccessDesigning Quasi-Experimental Single Participant Studies for Targeted Genetic Therapies with a One-Off Impact
Background: Genetic therapies aim to create targeted interventions that treat, prevent or manage genetic disorders, holding substantial promise for many pediatric diseases with underlying genetic causes. As emerging genetic therapies are increasingly being tailored to individual patients, evaluating their efficacy is challenging. Standard N-of-1 trial designs that require repeated crossovers between experimental and control conditions are infeasible as many genetic therapies produce one-time, irreversible effects. Quasi-experimental single-participant designs with pre- and post- intervention periods are a promising alternative in this context where interrupted time series (ITS) analysis can be applied. Herein, we evaluated and compared different design and statistical elements for single participant studies of novel genetic therapies. Methods: We simulated designs using pre- and post-intervention treatment periods examined with ITS models under different assumptions about treatment effects. Changes in a continuous study outcome were assumed to be linear with varying standard deviations (SD). Different frequentist and Bayesian statistical models were compared. Trial performance was evaluated across varying pre-treatment lengths, effect sizes, outcome measurement frequencies, and outcome SD. Patient and family engagement examined the feasibility of study design elements. Results: Using frequentist methods, three selected statistical models achieved similar optimal performance for a study duration of 2 years, yielding power of approximately 80% or higher while maintaining type I error rates around 5%. Simulations suggested studies with balanced pre-post intervention period lengths, larger treatment effects, lower outcome SD, and more frequent outcome assessments had the highest statistical power. Type I error rates were insensitive to outcome SD changes. Less frequent outcome measurement improved trial feasibility from a family perspective. Similar performance was observed when applying Bayesian analyses with minimally informative priors under the same trial design assumptions. Incorporating patient and caregiver perspectives identified additional strategies to improve feasibility and acceptability of the trial designs beyond statistical considerations. Conclusions: Quasi-experimental single participant studies with ITS analysis provide a feasible framework for evaluating novel genetic treatment effect in rare diseases. Appropriate statistical approaches and design parameters are critical for achieving adequate power while maintaining type I error control. Meaningful patient and family engagement during study design is critical for feasibility.
- 13 June 2026
- Published by Springer Nature in Journal of Autism and Developmental Disorders
Traumatic Experiences and Major Life Stressors in Children and Youth With Neurodevelopmental Disorders
Traumatic experiences adversely affect mental health; children with neurodevelopmental disorders (NDDs) may be more vulnerable to these adverse effects. The objective of this study was to examine the prevalence, types, and clinical correlates of traumatic experiences and major life stressors in children and youth with NDDs. A longitudinal retrospective cohort study was conducted using electronic medical records from a large tertiary program supporting children and youth diagnosed with autism or intellectual disability and persistent behavioural or mental health concerns. Those with and without a documented history of trauma/major stressors were compared regarding clinical and demographic characteristics; longitudinal associations with crisis service utilization were examined using survival models. Of 389 individuals (94% autism, 40% intellectual disability; 17% female; mean age 10.7 ± 3.1 years), 58 (15%) had a recorded trauma/major stressor, most commonly physical assault/abuse (3%) or family member death/estrangement (3%). Those with prior trauma/stressors were less likely to be female (5% vs. 19%, p = 0.01) or minimally-verbal (22% vs. 53%, p < 0.001); they had more suicidality (29% vs. 13%, p = 0.009), aggression (91% vs. 78%, p = 0.01), crisis service utilization (57% vs. 32%, p = 0.002), and psychotropic polypharmacy (3 vs. 2 medications, p < 0.01). Older age, past crisis service use, financial strain, and more allied health supports, but not past trauma/stressors, were associated with subsequent crisis service use. Children and youth with NDDs and a history of traumatic experiences or major life stressors had more mental health and behavioural symptoms. Trauma and major stressors may be clinically under-identified in those with minimal verbal communication.
- 13 June 2026
- Published by Springer Nature in Journal of Autism and Developmental Disorders
Traumatic Experiences and Major Life Stressors in Children and Youth With Neurodevelopmental Disorders
Traumatic experiences adversely affect mental health; children with neurodevelopmental disorders (NDDs) may be more vulnerable to these adverse effects. The objective of this study was to examine the prevalence, types, and clinical correlates of traumatic experiences and major life stressors in children and youth with NDDs. A longitudinal retrospective cohort study was conducted using electronic medical records from a large tertiary program supporting children and youth diagnosed with autism or intellectual disability and persistent behavioural or mental health concerns. Those with and without a documented history of trauma/major stressors were compared regarding clinical and demographic characteristics; longitudinal associations with crisis service utilization were examined using survival models. Of 389 individuals (94% autism, 40% intellectual disability; 17% female; mean age 10.7 ± 3.1 years), 58 (15%) had a recorded trauma/major stressor, most commonly physical assault/abuse (3%) or family member death/estrangement (3%). Those with prior trauma/stressors were less likely to be female (5% vs. 19%, p = 0.01) or minimally-verbal (22% vs. 53%, p < 0.001); they had more suicidality (29% vs. 13%, p = 0.009), aggression (91% vs. 78%, p = 0.01), crisis service utilization (57% vs. 32%, p = 0.002), and psychotropic polypharmacy (3 vs. 2 medications, p < 0.01). Older age, past crisis service use, financial strain, and more allied health supports, but not past trauma/stressors, were associated with subsequent crisis service use. Children and youth with NDDs and a history of traumatic experiences or major life stressors had more mental health and behavioural symptoms. Trauma and major stressors may be clinically under-identified in those with minimal verbal communication.
- Open Access
An n ‐of‐1 gene‐directed drug repurposing trial for an ultrarare genetic condition
Objective: Gain‐of‐function (GoF) variants in the KCNC1 potassium channel subunit gene (Kv3.1) cause motor/cognitive delays and hypotonia and have been associated with seizures. Fluoxetine has inhibitory effects on Kv3.1. However, open‐label nonrandomized administration is insufficient to guide clinical decision‐making in ultrarare conditions. This 40‐week randomized, double‐blind, n ‐of‐1 trial evaluated the safety and effectiveness of fluoxetine for motor development in a 2‐year, 10‐month‐old female child with a GoF KCNC1 variant. Methods: This study used an ABA phase design (placebo–fluoxetine–placebo), with randomization and blinding of treatment transition moments. The active treatment, fluoxetine powder, was provided at 2.5 mg (low dose) and subsequently 5 mg (target dose) per day. Motor developmental was measured using the parent‐reported Early Motor Questionnaire (EMQ), completed weekly. Secondary outcomes included cognitive and adaptive skills and other parent target symptoms (nystagmus, communication, purposeful hand movements). Results: Treatment with fluoxetine was associated with a 6.61‐point gain on the EMQ (95% credible interval [CrI] = −.53 to 14.78), beyond the effects of time (.52 points/week, 95% CrI = .28–.91). Treatment was well tolerated; possible withdrawal irritability emerged during the second placebo phase. A higher dose was associated with a larger treatment effect on the EMQ (2.5 mg = 6.81, 95% CrI = −.43 to 14.56; 5 mg = 8.68, 95% CrI = −4.29 to 21.76). Secondary outcomes showed significant improvements in purposeful hand movements (−.65, 95% CrI = −1.27 to −.003, on a 7‐point scale), and there were small increases in adaptive behavior and cognitive skills during the trial. Clinical biomarkers suggested a shift toward increased excitation on electroencephalogram and electroretinogram. Significance: Fluoxetine treatment was possibly associated with increased motor skill development in a young child with KCNC1 ‐related disorder involving a GoF variant. Trials studying developmental endpoints require innovative designs; this study provides a template for treatment assessment in ultrarare genetic neurodevelopmental disorders.
Open AccessAn n ‐of‐1 gene‐directed drug repurposing trial for an ultrarare genetic condition
Objective: Gain‐of‐function (GoF) variants in the KCNC1 potassium channel subunit gene (Kv3.1) cause motor/cognitive delays and hypotonia and have been associated with seizures. Fluoxetine has inhibitory effects on Kv3.1. However, open‐label nonrandomized administration is insufficient to guide clinical decision‐making in ultrarare conditions. This 40‐week randomized, double‐blind, n ‐of‐1 trial evaluated the safety and effectiveness of fluoxetine for motor development in a 2‐year, 10‐month‐old female child with a GoF KCNC1 variant. Methods: This study used an ABA phase design (placebo–fluoxetine–placebo), with randomization and blinding of treatment transition moments. The active treatment, fluoxetine powder, was provided at 2.5 mg (low dose) and subsequently 5 mg (target dose) per day. Motor developmental was measured using the parent‐reported Early Motor Questionnaire (EMQ), completed weekly. Secondary outcomes included cognitive and adaptive skills and other parent target symptoms (nystagmus, communication, purposeful hand movements). Results: Treatment with fluoxetine was associated with a 6.61‐point gain on the EMQ (95% credible interval [CrI] = −.53 to 14.78), beyond the effects of time (.52 points/week, 95% CrI = .28–.91). Treatment was well tolerated; possible withdrawal irritability emerged during the second placebo phase. A higher dose was associated with a larger treatment effect on the EMQ (2.5 mg = 6.81, 95% CrI = −.43 to 14.56; 5 mg = 8.68, 95% CrI = −4.29 to 21.76). Secondary outcomes showed significant improvements in purposeful hand movements (−.65, 95% CrI = −1.27 to −.003, on a 7‐point scale), and there were small increases in adaptive behavior and cognitive skills during the trial. Clinical biomarkers suggested a shift toward increased excitation on electroencephalogram and electroretinogram. Significance: Fluoxetine treatment was possibly associated with increased motor skill development in a young child with KCNC1 ‐related disorder involving a GoF variant. Trials studying developmental endpoints require innovative designs; this study provides a template for treatment assessment in ultrarare genetic neurodevelopmental disorders.
- Open Access
- 24 April 2025
- Published by Springer Nature in Journal of Neurodevelopmental Disorders
- Vol. 17 (1) , 1-11
Psychopharmacology in children with genetic disorders of epigenetic and chromatin regulation
Objective: Hundreds of rare genetic variants associated with autism or intellectual disability have been identified, and many impact genes known to have a primary epigenetic/chromatin regulatory function. The objective of this study was to examine and compare behavioural profiles and longitudinal psychotropic treatment patterns in children with epigenetic/chromatin variants, other rare variants impacting neurodevelopment, or no known genetic condition. Methods: Using electronic medical records from a pediatric psychopharmacology program for children with autism or intellectual disability, we compared clinical characteristics, longitudinal psychotropic medication profiles and side effects between those with and without a rare genetic variant, and by variant subtype [epigenetic/chromatin regulation or other variant]. Results: A total of 331 children attended 2724 unique medical visits between 2019 and 2022, with a mean of 8 follow-up visits over 3.4 years. Nine children (3%) had variants in epigenetic/chromatin regulatory genes (EC), twenty-three children (7%) had other rare genetic variants (OTH), and the rest had no reported variant (NR, n = 299, 90%). Those with a rare genetic variant (EC or OTH) were more likely to have an intellectual disability and had a greater number of co-occurring physical health conditions (p < 0.01). Overall, 66% of psychotropic medications were continued for ≥ 3 visits, while 26% were discontinued. Rates of psychotropic polypharmacy, medication patterns, behavioural challenges, and co-occurring developmental diagnoses were similar between genetic groups. Analyses uncorrected for multiple comparisons suggested those with genetic variants were more likely to experience drowsiness/sedation as a side effect (EC 33%, OTH 35%, NR 16%, p < 0.05); weight gain as a side effect was also higher in the epigenetic/chromatin group (EC 50% vs OTH 11%). Conclusion: Genetic classification of neurodevelopmental disorders (NDDs) may help anticipate treatment tolerability; additional prescribing considerations may be needed for those with rare variants. Current psychotropic prescribing practices do not differ across rare genetic NDD subgroups.
- 24 April 2025
- Published by Springer Nature in Journal of Neurodevelopmental Disorders
- Vol. 17 (1) , 1-11
Open AccessPsychopharmacology in children with genetic disorders of epigenetic and chromatin regulation
Objective: Hundreds of rare genetic variants associated with autism or intellectual disability have been identified, and many impact genes known to have a primary epigenetic/chromatin regulatory function. The objective of this study was to examine and compare behavioural profiles and longitudinal psychotropic treatment patterns in children with epigenetic/chromatin variants, other rare variants impacting neurodevelopment, or no known genetic condition. Methods: Using electronic medical records from a pediatric psychopharmacology program for children with autism or intellectual disability, we compared clinical characteristics, longitudinal psychotropic medication profiles and side effects between those with and without a rare genetic variant, and by variant subtype [epigenetic/chromatin regulation or other variant]. Results: A total of 331 children attended 2724 unique medical visits between 2019 and 2022, with a mean of 8 follow-up visits over 3.4 years. Nine children (3%) had variants in epigenetic/chromatin regulatory genes (EC), twenty-three children (7%) had other rare genetic variants (OTH), and the rest had no reported variant (NR, n = 299, 90%). Those with a rare genetic variant (EC or OTH) were more likely to have an intellectual disability and had a greater number of co-occurring physical health conditions (p < 0.01). Overall, 66% of psychotropic medications were continued for ≥ 3 visits, while 26% were discontinued. Rates of psychotropic polypharmacy, medication patterns, behavioural challenges, and co-occurring developmental diagnoses were similar between genetic groups. Analyses uncorrected for multiple comparisons suggested those with genetic variants were more likely to experience drowsiness/sedation as a side effect (EC 33%, OTH 35%, NR 16%, p < 0.05); weight gain as a side effect was also higher in the epigenetic/chromatin group (EC 50% vs OTH 11%). Conclusion: Genetic classification of neurodevelopmental disorders (NDDs) may help anticipate treatment tolerability; additional prescribing considerations may be needed for those with rare variants. Current psychotropic prescribing practices do not differ across rare genetic NDD subgroups.
- Open Access
- 25 July 2024
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 70 (5) , 372-381
Predictors of Depressive Symptoms in Autistic Youth—A Longitudinal Study From the Province of Ontario Neurodevelopmental Disorders (POND) Network: Prédicteurs des symptômes dépressifs chez les jeunes autistes—une étude longitudinale du Réseau des troubles neurodéveloppementaux de la province de l’Ontario (réseau POND)
Objective: The objective of this study was to identify longitudinal predictors of depressive symptoms in autistic children and youth. Methods: Participants were youth with a diagnosis of autism who were part of the Province of Ontario Neurodevelopmental Disorders Network longitudinal substudy. Depressive symptoms were assessed using the child behaviour checklist (CBCL) affective problems subscale. Univariate and multivariable logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between clinical and demographic characteristics at baseline (T1) and clinically elevated depressive symptoms (CEDS) approximately 4 years later (T2). Results: The mean age of participants ( n = 75) at T1 was 9.8 years ( SD = 2.7) and at T2 was 14.1 years ( SD = 2.8). A total of 37% and 35% of participants had CEDS at T1 and T2, respectively. Additionally, 24% of participants had CEDS at both T1 and T2. T1 characteristics associated with T2 CEDS were: loneliness (OR = 3.0, 95% CI, 1.1 to 8.8), self-harm (OR = 4.0, 95% CI, 1.1 to 16.9), suicidal ideation (OR = 3.9, 95% CI, 1.0 to 16.5), more social and adaptive skills (OR = 0.3, 95% CI, 0.1 to 0.9), elevated restricted and repetitive behaviours (OR = 3.8, 95% CI, 1.3 to 11.6), psychotropic medication use (OR = 3.0, 95% CI, 1.1 to 8.4), attention-deficient/hyperactivity disorder (OR = 2.8, 95% CI, 1.1 to 7.8), and T1 CEDS (OR = 8.8, 95% CI, 3.1 to 27.0) (uncorrected for multiple comparisons). Associations persisted after adjusting for age and intelligence quotient (IQ) differences. Age, sex, IQ, teasing/bullying on the CBCL, family psychiatric history and family income were not associated with T2 CEDS. Conclusion: Our results highlight both high prevalence and high potential for the persistence of depressive symptoms in autism and emphasize the importance of early support to address loneliness and social participation. Plain Language Summary Title: Study assessing risk factors for depression in autistic youth
- 25 July 2024
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 70 (5) , 372-381
Open AccessPredictors of Depressive Symptoms in Autistic Youth—A Longitudinal Study From the Province of Ontario Neurodevelopmental Disorders (POND) Network: Prédicteurs des symptômes dépressifs chez les jeunes autistes—une étude longitudinale du Réseau des troubles neurodéveloppementaux de la province de l’Ontario (réseau POND)
Objective: The objective of this study was to identify longitudinal predictors of depressive symptoms in autistic children and youth. Methods: Participants were youth with a diagnosis of autism who were part of the Province of Ontario Neurodevelopmental Disorders Network longitudinal substudy. Depressive symptoms were assessed using the child behaviour checklist (CBCL) affective problems subscale. Univariate and multivariable logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between clinical and demographic characteristics at baseline (T1) and clinically elevated depressive symptoms (CEDS) approximately 4 years later (T2). Results: The mean age of participants ( n = 75) at T1 was 9.8 years ( SD = 2.7) and at T2 was 14.1 years ( SD = 2.8). A total of 37% and 35% of participants had CEDS at T1 and T2, respectively. Additionally, 24% of participants had CEDS at both T1 and T2. T1 characteristics associated with T2 CEDS were: loneliness (OR = 3.0, 95% CI, 1.1 to 8.8), self-harm (OR = 4.0, 95% CI, 1.1 to 16.9), suicidal ideation (OR = 3.9, 95% CI, 1.0 to 16.5), more social and adaptive skills (OR = 0.3, 95% CI, 0.1 to 0.9), elevated restricted and repetitive behaviours (OR = 3.8, 95% CI, 1.3 to 11.6), psychotropic medication use (OR = 3.0, 95% CI, 1.1 to 8.4), attention-deficient/hyperactivity disorder (OR = 2.8, 95% CI, 1.1 to 7.8), and T1 CEDS (OR = 8.8, 95% CI, 3.1 to 27.0) (uncorrected for multiple comparisons). Associations persisted after adjusting for age and intelligence quotient (IQ) differences. Age, sex, IQ, teasing/bullying on the CBCL, family psychiatric history and family income were not associated with T2 CEDS. Conclusion: Our results highlight both high prevalence and high potential for the persistence of depressive symptoms in autism and emphasize the importance of early support to address loneliness and social participation. Plain Language Summary Title: Study assessing risk factors for depression in autistic youth
- Open Access
- 6 April 2024
- Published by Springer Nature in npj Genomic Medicine
- Vol. 9 (1) , 1-8
Consensus reporting guidelines to address gaps in descriptions of ultra-rare genetic conditions
Genome-wide sequencing and genetic matchmaker services are propelling a new era of genotype-driven ascertainment of novel genetic conditions. The degree to which reported phenotype data in discovery-focused studies address informational priorities for clinicians and families is unclear. We identified reports published from 2017 to 2021 in 10 genetics journals of novel Mendelian disorders. We adjudicated the quality and detail of the phenotype data via 46 questions pertaining to six priority domains: (I) Development, cognition, and mental health; (II) Feeding and growth; (III) Medication use and treatment history; (IV) Pain, sleep, and quality of life; (V) Adulthood; and (VI) Epilepsy. For a subset of articles, all subsequent published follow-up case descriptions were identified and assessed in a similar manner. A modified Delphi approach was used to develop consensus reporting guidelines, with input from content experts across four countries. In total, 200 of 3243 screened publications met inclusion criteria. Relevant phenotypic details across each of the 6 domains were rated superficial or deficient in >87% of papers. For example, less than 10% of publications provided details regarding neuropsychiatric diagnoses and “behavioural issues”, or about the type/nature of feeding problems. Follow-up reports (n = 95) rarely contributed this additional phenotype data. In summary, phenotype information relevant to clinical management, genetic counselling, and the stated priorities of patients and families is lacking for many newly described genetic diseases. The PHELIX (PHEnotype LIsting fiX) reporting guideline checklists were developed to improve phenotype reporting in the genomic era.
- 6 April 2024
- Published by Springer Nature in npj Genomic Medicine
- Vol. 9 (1) , 1-8
Open AccessConsensus reporting guidelines to address gaps in descriptions of ultra-rare genetic conditions
Genome-wide sequencing and genetic matchmaker services are propelling a new era of genotype-driven ascertainment of novel genetic conditions. The degree to which reported phenotype data in discovery-focused studies address informational priorities for clinicians and families is unclear. We identified reports published from 2017 to 2021 in 10 genetics journals of novel Mendelian disorders. We adjudicated the quality and detail of the phenotype data via 46 questions pertaining to six priority domains: (I) Development, cognition, and mental health; (II) Feeding and growth; (III) Medication use and treatment history; (IV) Pain, sleep, and quality of life; (V) Adulthood; and (VI) Epilepsy. For a subset of articles, all subsequent published follow-up case descriptions were identified and assessed in a similar manner. A modified Delphi approach was used to develop consensus reporting guidelines, with input from content experts across four countries. In total, 200 of 3243 screened publications met inclusion criteria. Relevant phenotypic details across each of the 6 domains were rated superficial or deficient in >87% of papers. For example, less than 10% of publications provided details regarding neuropsychiatric diagnoses and “behavioural issues”, or about the type/nature of feeding problems. Follow-up reports (n = 95) rarely contributed this additional phenotype data. In summary, phenotype information relevant to clinical management, genetic counselling, and the stated priorities of patients and families is lacking for many newly described genetic diseases. The PHELIX (PHEnotype LIsting fiX) reporting guideline checklists were developed to improve phenotype reporting in the genomic era.
- 7 March 2024
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 63 (6) , 571-573
Selective Serotonin Reuptake Inhibitor Treatment Post Gene Therapy for an Ultrarare Neurometabolic Disorder (AADC Deficiency)
- 7 March 2024
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 63 (6) , 571-573
Selective Serotonin Reuptake Inhibitor Treatment Post Gene Therapy for an Ultrarare Neurometabolic Disorder (AADC Deficiency)
- Open Access
Gaps in the phenotype descriptions of ultra-rare genetic conditions: review and multicenter consensus reporting guidelines
Background: Genome-wide sequencing and genetic matchmaker services are propelling a new era of genotype-first ascertainment of novel genetic conditions. The degree to which reported phenotype data in discovery-focused studies address informational priorities for clinicians and families is unclear. Methods: We identified reports published from 2017-2021 in ten genetics journals of novel Mendelian disorders ascertained genotype-first. We adjudicated the quality and detail of the phenotype data via 46 questions pertaining to six priority domains: (I) Development, cognition, and mental health; (II) Feeding and growth; (III) Medication use and treatment history; (IV) Pain, sleep, and quality of life; (V) Adulthood; and (VI) Epilepsy. For a subset of articles, all subsequent published follow-up case descriptions were identified and assessed in a similar manner. A modified Delphi approach was used to develop consensus reporting guidelines, with input from content experts across four countries. Results: In total, 200 of 3243 screened publications met inclusion criteria. Relevant phenotypic details across each of the six domains were rated superficial or deficient in >87% of papers. For example, less than 10% of publications provided details regarding neuropsychiatric diagnoses and behavioural issues, or about the type/nature of feeding problems. Follow-up reports (n=95) rarely addressed the limitations of the original reports. Reporting guidelines were developed for each domain. Conclusion: Phenotype information relevant to clinical management, genetic counseling, and the stated priorities of patients and families is lacking for many newly described genetic diseases. Use of the proposed guidelines could improve phenotype reporting in the genomic era.
Open AccessGaps in the phenotype descriptions of ultra-rare genetic conditions: review and multicenter consensus reporting guidelines
Background: Genome-wide sequencing and genetic matchmaker services are propelling a new era of genotype-first ascertainment of novel genetic conditions. The degree to which reported phenotype data in discovery-focused studies address informational priorities for clinicians and families is unclear. Methods: We identified reports published from 2017-2021 in ten genetics journals of novel Mendelian disorders ascertained genotype-first. We adjudicated the quality and detail of the phenotype data via 46 questions pertaining to six priority domains: (I) Development, cognition, and mental health; (II) Feeding and growth; (III) Medication use and treatment history; (IV) Pain, sleep, and quality of life; (V) Adulthood; and (VI) Epilepsy. For a subset of articles, all subsequent published follow-up case descriptions were identified and assessed in a similar manner. A modified Delphi approach was used to develop consensus reporting guidelines, with input from content experts across four countries. Results: In total, 200 of 3243 screened publications met inclusion criteria. Relevant phenotypic details across each of the six domains were rated superficial or deficient in >87% of papers. For example, less than 10% of publications provided details regarding neuropsychiatric diagnoses and behavioural issues, or about the type/nature of feeding problems. Follow-up reports (n=95) rarely addressed the limitations of the original reports. Reporting guidelines were developed for each domain. Conclusion: Phenotype information relevant to clinical management, genetic counseling, and the stated priorities of patients and families is lacking for many newly described genetic diseases. Use of the proposed guidelines could improve phenotype reporting in the genomic era.
- Open Access
- 1 August 2023
- Published by Wiley in Autism Research
- Vol. 16 (8) , 1600-1608
Linkage of whole genome sequencing and administrative health data in autism: A proof of concept study
Whether genetic testing in autism can help understand longitudinal health outcomes and health service needs is unclear. The objective of this study was to determine whether carrying an autism‐associated rare genetic variant is associated with differences in health system utilization by autistic children and youth. This retrospective cohort study examined 415 autistic children/youth who underwent genome sequencing and data collection through a translational neuroscience program (Province of Ontario Neurodevelopmental Disorders Network). Participant data were linked to provincial health administrative databases to identify historical health service utilization, health care costs, and complex chronic medical conditions during a 3‐year period. Health administrative data were compared between participants with and without a rare genetic variant in at least 1 of 74 genes associated with autism. Participants with a rare variant impacting an autism‐associated gene (n = 83, 20%) were less likely to have received psychiatric care (at least one psychiatrist visit: 19.3% vs. 34.3%, p = 0.01; outpatient mental health visit: 66% vs. 77%, p = 0.04). Health care costs were similar between groups (median: $5589 vs. $4938, p = 0.4) and genetic status was not associated with odds of being a high‐cost participant (top 20%) in this cohort. There were no differences in the proportion with complex chronic medical conditions between those with and without an autism‐associated genetic variant. Our study highlights the feasibility and potential value of genomic and health system data linkage to understand health service needs, disparities, and health trajectories in individuals with neurodevelopmental conditions.
- 1 August 2023
- Published by Wiley in Autism Research
- Vol. 16 (8) , 1600-1608
Open AccessLinkage of whole genome sequencing and administrative health data in autism: A proof of concept study
Whether genetic testing in autism can help understand longitudinal health outcomes and health service needs is unclear. The objective of this study was to determine whether carrying an autism‐associated rare genetic variant is associated with differences in health system utilization by autistic children and youth. This retrospective cohort study examined 415 autistic children/youth who underwent genome sequencing and data collection through a translational neuroscience program (Province of Ontario Neurodevelopmental Disorders Network). Participant data were linked to provincial health administrative databases to identify historical health service utilization, health care costs, and complex chronic medical conditions during a 3‐year period. Health administrative data were compared between participants with and without a rare genetic variant in at least 1 of 74 genes associated with autism. Participants with a rare variant impacting an autism‐associated gene (n = 83, 20%) were less likely to have received psychiatric care (at least one psychiatrist visit: 19.3% vs. 34.3%, p = 0.01; outpatient mental health visit: 66% vs. 77%, p = 0.04). Health care costs were similar between groups (median: $5589 vs. $4938, p = 0.4) and genetic status was not associated with odds of being a high‐cost participant (top 20%) in this cohort. There were no differences in the proportion with complex chronic medical conditions between those with and without an autism‐associated genetic variant. Our study highlights the feasibility and potential value of genomic and health system data linkage to understand health service needs, disparities, and health trajectories in individuals with neurodevelopmental conditions.